Clinical trial · Observational
Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors
Non - Interventional, Retrospective Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To understand the epidemiology, treatment patterns and outcomes of patients with metastatic Renal Cell Carcinoma (mRCC). Data from mRCC patients who received cabozantinib versus non-cabozantinib Tyrosine Kinase Inhibitor (TKI) (a type of targeted cancer drug) immediately after Check Point Inhibitor (CPI) treatment (a type of immunotherapy that blocks proteins that stop the immune system from attacking the cancer cells) in US community oncology practices will be analyzed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced or Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC | Drug | — | UNRESOLVED |
| Cabozantinib monotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- cabozantinib arm
- interventionNames
- Drug: Cabozantinib monotherapy
- label
- non cabozantinib Tyrosine Kinase Inhibitors (TKI) arm
- interventionNames
- Drug: All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC
Primary outcomes (1)
- measure
- 6 months Real-World Response Rate
- timeFrame
- From start of index treatment until 6 months of follow up or end of the treatment or death whichever occurs first
Secondary outcomes (9)
- measure
- Real-World Overall Response Rate
- timeFrame
- From start of index treatment until end of the treatment or death whichever occurs first
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Evidence of metastatic Renal Cell Carcinoma (mRCC) during the study period (May 01, 2016 to March 31, 2020); * Patients who received cabozantinib or non-cabozantinib TKI regimens during identification period (May 01, 2016 to September 30, 2019); * Patients who received CPIs, as monotherapy, or in combination with a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor (e.g. ipilimumab+nivolumab), as the latest treatment for mRCC administrated before cabozantinib or other TKI therapy; * Patients ≥ 18 years of age as of their index date * Patients who received care at a US Oncology Network site * Patients with ≥ 2 visits within the US Oncology Network. Exclusion Criteria: * Patients enrolled in a clinical trial at any time during index period * Patients receiving treatment for another documented primary cancer diagnoses during the study period
References
Publications (0)
Data not yet available